Brief: Vistagen Initiates PALISADE-3 Phase 3 Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder
01/04/2024 17:08
April 1 (Reuters) - Vistagen Therapeutics Inc VTGN.O :
* VISTAGEN THERAPEUTICS INC: PLANS TO INITIATE PALISADE-4,
WHICH
WILL BE A REPLICATE OF PALISADE-3, DURING SECOND HALF OF 2024
* VISTAGEN INITIATES PALISADE-3 PHASE 3 STUDY OF FASEDIENOL
FOR
THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER FOLLOWING
POSITIVE RESULTS OF PALISADE-2
Source text for Eikon: ID:nBw5KhlPMa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors